Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Withdrawn 3Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Other 3

Conditions

Mucositis 3Hematologic Neoplasms 3Graft vs Host Disease 1

Interventions

angiotensin I (1-7) 3Leuprolide 2Hydrocortisone 2Bariatric Surgery 2methylnaltrexone 1lorcaserin 1apraglutide 1Vitamin E 1Vaccinium myrtillus extract 1Therapeutics 1Surveys and Questionnaires 1Standard of Care 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Quality of Life 1Practice Guidelines as Topic 1Ovidrel 1Nicotine 1Monitoring, Physiologic 1Midazolam 1Losartan 1Lansoprazole 1Holistic Health 1High-Energy Shock Waves 1Furosemide 1Fibroblast Growth Factor 7 1Exercise 1Diet, Vegetarian 1Diet, Vegan 1Diet Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × angiotensin I (1-7) × Other × Clear all
NCT01554254 2016-08-31

Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation

Tarix Pharmaceuticals

Phase 2 Withdrawn
OtherOther hematologic neoplasm

Hematologic Neoplasms, Mucositis

NCT01882374 2016-08-31

Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation

Tarix Pharmaceuticals

Phase 2 Withdrawn
OtherOther hematologic neoplasm

Hematologic Neoplasms, Mucositis

NCT01882387 2016-08-31

Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Tarix Pharmaceuticals

Phase 2 Withdrawn
OtherOther hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡